Latest

Jul 17, 2026, 18:44 Arvind Krishna Rebuilt IBM Around Software. Now He Has to Make the AI Stack Outrun the Mainframe Cycle

Jul 17, 2026, 16:45 Nikhil Kamath Turned Market Access Into a Media Platform. Influence Now Needs Clearer Boundaries

Jul 17, 2026, 13:40 Lucy Guo Built Passes Around Creator Ownership. Trust Must Become the Subscription Advantage

Jul 17, 2026, 10:35 Shashank Kumar Is Rewiring Razorpay Around Payment Success. Reliability Has to Pay

Jul 16, 2026, 16:45 Ritesh Agarwal Has Taken PRISM Back to the IPO Gate. Investors Will Price the Quality of OYO's Profit

Jul 16, 2026, 15:37 Nikesh Arora Made Palo Alto Networks Cybersecurity’s Consolidator. Now He Has to Make the Stack Work as One

Jul 16, 2026, 13:40 Gukesh Dommaraju Became Chess's Youngest World Champion. Defending the Crown Is a Different Business

Jul 16, 2026, 10:35 Scott Wu Joined Devin With Windsurf. The Combined Product Must Earn a US$26 Billion Valuation

Person: Demis Hassabis

Demis Hassabis, Co-founder and Chief Executive Officer of Google DeepMind

Demis Hassabis Moved DeepMind Deeper Into the Laboratory. Scientific AI Needs a Verification Business Model

Demis Hassabis is building a wider scientific-AI stack around AlphaGenome and Co-Scientist. The opportunity is large, but laboratories need reproducible gains rather than fluent novelty.

Demis Hassabis, co-founder and Chief Executive Officer of Google DeepMind

For Demis Hassabis, Gemini’s Leap Into Action Makes Scientific Proof the Hard Part

Demis Hassabis has turned Google DeepMind into the research engine behind products used at vast scale. Its next challenge is to preserve scientific credibility while delivering on Alphabet’s historic AI investment.

Demis Hassabis, Co-founder and Chief Executive Officer of Google DeepMind and Founder of Isomorphic Labs

Demis Hassabis Raised $2.1 Billion to Industrialise AI Drug Design. The Clinic Has Yet to Validate the Engine

Demis Hassabis has given Isomorphic Labs the capital and computing ambition of a technology platform. The harder test is whether its drug candidates can survive the slower economics of human biology.